ArticleAmerican journal of physiology. Renal physiology2015
Arginase inhibition: a new treatment for preventing progression of established diabetic nephropathy.
Article in American journal of physiology. Renal physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Association between life's essential 8 and diabetic kidney disease: a population-based study.Renal failure · 2025Article
- Insulin restores renal neprilysin (NEP) and attenuates the shedding of urinary NEP and KIM-1 in diabetic Akita mice.Frontiers in pharmacology · 2025Article
- Supplemented Very Low Protein Diet (sVLPD) in Patients with Advanced Chronic Renal Failure: Clinical and Economic Benefits.Nutrients · 2023Observational
- Arginase 2 negatively regulates sorafenib-induced cell death by mediating ferroptosis in melanoma.Acta biochimica et biophysica Sinica · 2022Article
- Arginase: Biological and Therapeutic Implications in Diabetes Mellitus and Its Complications.Oxidative medicine and cellular longevity · 2022Review
- Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.Nature reviews. Nephrology · 2021Review
- Homoarginine ameliorates diabetic nephropathy independent of nitric oxide synthase-3.Physiological reports · 2021Article
- Arginase II Plays a Central Role in the Sexual Dimorphism of Arginine Metabolism in C57BL/6 Mice.The Journal of nutrition · 2020Article
- Selective inhibition of arginase-2 in endothelial cells but not proximal tubules reduces renal fibrosis.JCI insight · 2020Article
- Connectivity mapping of glomerular proteins identifies dimethylaminoparthenolide as a new inhibitor of diabetic kidney disease.Scientific reports · 2020Article
- Enhancing kidney DDAH-1 expression by adenovirus delivery reduces ADMA and ameliorates diabetic nephropathy.American journal of physiology. Renal physiology · 2020Article
- l-Homoarginine supplementation prevents diabetic kidney damage.Physiological reports · 2019Article
- Roles of eNOS in atherosclerosis treatment.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Review
- LncRNA PRINS is involved in the development of nephropathy in patients with diabetes via interaction with Smad7.Experimental and therapeutic medicine · 2019Article
- Mechanisms of Diabetes-Induced Endothelial Cell Senescence: Role of Arginase 1.International journal of molecular sciences · 2018Article
- Arginase: A Multifaceted Enzyme Important in Health and Disease.Physiological reviews · 2018Review
- Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy.Journal of the American Society of Nephrology : JASN · 2018Article
- Distinct roles of arginases 1 and 2 in diabetic nephropathy.American journal of physiology. Renal physiology · 2017Article
- Arginase-2 mediates renal ischemia-reperfusion injury.American journal of physiology. Renal physiology · 2017Article
- Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.Kidney international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Our previous publication showed that inhibition of arginase prevents the development of diabetic nephropathy (DN). However, identification of targets that retard the progression of established DN-which is more clinically relevant-is lacking. Therefore, we tested the hypothesis that arginase inhibition would prevent the progression of established DN. Effects of arginase inhibition were compared with treatment with the angiotensin-converting enzyme inhibitor captopril, a current standard of care in DN. Experiments were conducted in Ins2(Akita) mice treated with the arginase inhibitor S-(2-boronoethyl)-l-cysteine (BEC) or captopril starting at 6 wk of age for 12 wk (early treatment) or starting at 12 wk of age for 6 wk (late treatment). Early and late treatment with BEC resulted in protection from DN as indicated by reduced albuminuria, histological changes, kidney macrophage infiltration, urinary thiobarbituric acid-reactive substances, and restored nephrin expression, kidney nitrate/nitrite, kidney endothelial nitric oxide synthase phosphorylation, and renal medullary blood flow compared with vehicle-treated Ins2(Akita) mice at 18 wk of age. Interestingly, early treatment with captopril reduced albuminuria, histological changes, and kidney macrophage infiltration without affecting the other parameters, but late treatment with captopril was ineffective. These findings highlight the importance of arginase inhibition as a new potential therapeutic intervention in both early and late stages of diabetic renal injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.